Target intelligence / Profile preview

DNA polymerase subunit gamma-2, mitochondrial (POLG2)

Target
POLG2
Molecular classification
Enzyme (DNA-directed DNA polymerase, mitochondrial), Accessory/protein subunit (polymerase processivity factor)
01

Overview

DNA polymerase subunit gamma-2, mitochondrial (POLG2) is the 55 kDa accessory subunit of the mitochondrial DNA polymerase gamma complex. The holoenzyme comprises one catalytic subunit (POLG) and a dimer of POLG2, forming a heterotrimeric structure. POLG2 enhances the affinity of the POLG catalytic subunit for DNA, increases processivity (enabling long-chain DNA synthesis), and confers salt tolerance to the complex. It fulfills essential functions in mitochondrial DNA replication and maintenance; mutations in POLG2 therefore result in depletion and deletions of mitochondrial genomes, presenting as progressive external ophthalmoplegia and other systemic manifestations. POLG2 directly binds DNA, can oligomerize, and is thought to play structure-specific roles in targeting forked or crossed DNA structures in the mitochondrial nucleoid. Genetic disruption leads to mitochondrial dysfunction and multisystemic disease; no direct drugs presently target POLG2 but its role is central to mitochondrial genetic stability.

Other names
POLG2HP55MTPOLBPEOA4POLBPOLG-BETAPOLGBpolymerase (DNA) gamma 2, accessory subunitDNA polymerase gamma 2, accessory subunitMTDPS16MTDPS16AMTDPS16BDNA polymerase gamma accessory 55 kDa subunitMitochondrial DNA polymerase accessory subunitp55Polymerase (DNA directed), gamma 2, accessory subunit
02

Mechanism of action

No drugs with a characterized mechanism targeting POLG2; inhibition would reduce mitochondrial DNA replication

03

Biological functions

Mitochondrial DNA replicationEnhancing DNA binding affinity for DNA polymerase gammaProcessive DNA synthesisAllosteric regulation of polymerase activity
04

Disease associations

Neurodegenerative disease (mitochondrial disorders)Mitochondrial depletion syndromeProgressive external ophthalmoplegia ("autosomal dominant progressive external ophthalmoplegia with mitochondrial DNA deletions")Ataxia, myopathy, hearing loss, parkinsonism (secondary to mtDNA depletion syndrome)Other multisystem mitochondrial diseases
05

Safety considerations

Mitochondrial toxicity if function disrupted (risk for cell energy depletion, multisystem failure)Embryonic lethality in knockout mouse modelsGenetic mutations may cause a variety of age-dependent, heritable mitochondrial diseases
06

Biomarkers

POLG2 mutations, especially missense mutations, may be biomarker for some mitochondrial pathologies

Beyond the preview

Go deeper on DNA polymerase subunit gamma-2, mitochondrial (POLG2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase subunit gamma-2, mitochondrial (POLG2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call